



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 19-710/S-032

Mallinckrodt/Tyco HealthCare
Attention: Edward R. Porter
Manager, Regulatory Affairs
675 McDonnell Blvd.
P.O. Box 5840
St. Louis, MO 63134

Dear Mr. Porter:

Please refer to your supplemental new drug application dated March 6, 2007, received March 7, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Optiray®(Ioversol) Injection.

We acknowledge receipt of your submission dated March 12, 2008.

This supplemental new drug application provides for A Radio Frequency Identification (RFID) tag to be embedded into the Optiray® label, which is placed on the outside of the syringe barrel following sterilization and inspection.

We completed our review of this application as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon enclosed labeling.

The final printed labeling (FPL) must be identical to the enclosed labeling.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 19-710/S-032". Approval of this submission by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Medical Imaging and Hematology Products and two copies of both the promotional materials and the package insert directly to:

April, 2008

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call James Moore, Regulatory Project Manager, at (301) 796-2050.

Sincerely,

{See appended electronic signature page}

Rafel Rieves, M.D.
Acting Director
Division of Medical Imaging and Hematology
Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Rafel Rieves

4/25/2008 03:30:11 PM